{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-047020","form_type":"8-K","ticker":"RNLXY","cik":"0001811115","company_name":"Renalytix plc","filed_at":"2024-04-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.265263+00:00","generated_at":"2026-06-03T12:12:15.699416+00:00","sec_items":["1.01","5.02","5.07","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Renalytix president McLain resigns, Howard Doran appointed; equity offering expanded","bullets":["Thomas McLain resigns as President effective April 30, 2024; severance includes 6 months base salary ($450K) and accelerated vesting of 12 months of options.","Howard Doran appointed President effective April 30, 2024; base salary increased to $350K from $300K.","Investor DB Capital exercised option to buy 1,333,334 additional shares at $0.375/share, raising net ~$0.5M.","Shareholders approved allotment of up to 26.8M new ordinary shares and related pre-emptive waivers with >98% support.","Original option exercise period extended to April 22, 2024 via letter agreement; total offering includes 4M shares at $0.375."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-047020","json":"https://secwatch.observer/filing/0000950170-24-047020.json","markdown":"https://secwatch.observer/filing/0000950170-24-047020.md","text":"https://secwatch.observer/filing/0000950170-24-047020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811115/000095017024047020/0000950170-24-047020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811115/000095017024047020/rnlx-20240417.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T12:12:15.699416+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"23f912d95a","claim":"Thomas McLain resigned as President at Renalytix plc.","evidence_excerpt":"On April 17, 2024, Thomas McLain notified the Company that he will resign as President of the Company, effective April 30, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1811115/000095017024047020/0000950170-24-047020-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"b3ecc0bad2","claim":"Howard Doran was appointed as President at Renalytix plc.","evidence_excerpt":"On April 23, 2024, the Company’s Board of Directors (the “ Board ”) appointed Howard Doran, currently the Company’s Chief Business Officer, to serve as the Company’s President, effective as of April 30, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1811115/000095017024047020/0000950170-24-047020-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"73415c9c4bbd1a2c6a38e524e9fed99b089d8995","claim":"Renalytix plc entered into Purchase Agreement with DB Capital Partners Healthcare, L.P. (effective 2024-04-05).","evidence_excerpt":"on April 5, 2024, Renalytix plc (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with DB Capital Partners Healthcare, L.P. (the “ Purchaser ”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1811115/000095017024047020/0000950170-24-047020-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"DB Capital Partners Healthcare, L.P."},{"label":"Effective","value":"2024-04-05"}],"fact_type":"material_agreement"},{"claim_id":"1c79e8b21fe20512fe25453f9b64e7558dc8904b","claim":"Renalytix plc shareholders approved Authorization of disapplication of pre-emption rights limited to shares of maximum aggregate nominal amount of £128,391 at the 2024-04-22 meeting.","evidence_excerpt":"Proposal 4 – Subject to and conditional upon the passing of Proposal 2, to authorize the disapplication of pre-emption rights limited to shares of a maximum aggregate nominal amount of £128,391. For Against Vote Withheld 45,853,622 4,859,914 120,004","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1811115/000095017024047020/0000950170-24-047020-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-04-22"}],"fact_type":"shareholder_vote"},{"claim_id":"2f18f9949f305dd380de2339ac1a6b919741eecb","claim":"Renalytix plc shareholders approved Authorization of allotment of shares and grant of rights to subscribe for or convert into shares up to aggregate nominal amount of £128,391 and further allotment in connection with pre-emptive offer at the 2024-04-22 meeting.","evidence_excerpt":"Proposal 2 – To authorize the allotment of shares and the grant of rights to subscribe for, or convert any security into, shares of the Company up to an aggregate nominal amount of £128,391 and the allotment of further equity securities up to an aggregate nominal amount of £122,277 in connection with a pre-emptive offer in favor of shareholders. For Against Vote Withheld 45,880,130 4,832,979 120,431","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1811115/000095017024047020/0000950170-24-047020-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-04-22"}],"fact_type":"shareholder_vote"},{"claim_id":"964904804537cd1423b4eb6fb3d42389b0587c51","claim":"Renalytix plc shareholders approved Authorization of allotment of ordinary shares up to aggregate nominal amount of £67,039.6025 (Second Tranche Placing Shares) at the 2024-04-22 meeting.","evidence_excerpt":"Proposal 1 – To authorize the al lotment of ordinary shares of £0.0025 each in the capital of the Company up to an aggregate nominal amount of £67,039.6025 (26,815,841 ordinary shares) (the “Second Tranche Placing Shares”). For Against Vote Withheld 50,091,780 621,329 120,431","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1811115/000095017024047020/0000950170-24-047020-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-04-22"}],"fact_type":"shareholder_vote"},{"claim_id":"c7f2b5df0810fb254200b101d505c770bfe256c2","claim":"Renalytix plc shareholders approved Authorization of disapplication of statutory pre-emption rights for Second Tranche Placing Shares and shareholder approval pursuant to Nasdaq 20% Rule at the 2024-04-22 meeting.","evidence_excerpt":"Proposal 3 – Subject to and conditional upon the passing of Proposal 1, to authorize (i) the disapplication of statutory pre-emption rights for the issue and allotment of the Second Tranche Placing Shares and (ii) shareholder approval pursuant to the Nasdaq 20% Rule. For Against Vote Withheld 50,072,092 641,404 120,044","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1811115/000095017024047020/0000950170-24-047020-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-04-22"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}